Axoft

Axoft is pioneering a next-generation neural interface platform that combines a novel, ultra-soft implantable material with high-density electrodes and AI-driven software. Founded in 2021 and based in Cambridge, Massachusetts, the company is addressing the critical limitations of current rigid and soft BCIs—namely tissue damage, signal drift, and low resolution—to enable stable, long-term recording and stimulation. Its integrated system, which includes a proprietary Brain Foundation Model, targets transformative applications in treating conditions like paralysis, depression, and movement disorders. Axoft is a private, pre-revenue company in the pre-clinical development stage, positioning itself at the convergence of advanced materials science, electronics, and artificial intelligence.

Bioinspired, ultra-soft neural implant material combined with ultra-high-density electrodes, integrated bidirectional electronics, and a proprietary AI Brain Foundation Model for decoding neural signals.

Axoft competes in the advanced BCI space with companies like Neuralink (high-density, rigid arrays), Synchron (endovascular stent-electrode), Paradromics (high-density cortical interface), and Blackrock Neurotech (established Utah array). Its key differentiator is the claimed combination of extreme softness (for biocompatibility) with ultra-high electrode density, a combination not yet demonstrated by competitors.